Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2024-08-29 Governance Information
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Corporate Governance Statement 13 pages 410.3KB
Governance Information Classification · 100% confidence The document is titled 'Corporate Governance Statement' and contains detailed disclosures about the company's corporate governance practices, board structure, board committees, director independence, and compliance with ASX Corporate Governance Principles and Recommendations. It includes detailed tables on governance policies, board evaluations, diversity policies, and director appointments and independence. The document is 15,000 characters long, indicating it is a full report rather than a brief announcement. The content aligns with governance information rather than financial results, management changes, or regulatory filings. Therefore, the document fits the category of Governance Information (CGR).
2024-08-29 English
Appendix 4G 11 pages 358.5KB
Governance Information Classification · 100% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a governance-related disclosure document for the financial year ended 30 June 2024 for Orthocell Limited. The text explains that Appendix 4G is a key to assist readers in locating governance disclosures made under Listing Rule 4.10.3 and is lodged with the ASX alongside the annual report. The document is not the annual report itself but a supplementary governance disclosure form. It contains detailed information about compliance with corporate governance principles and recommendations, including board charters, nomination committees, diversity policies, and evaluation processes. The document is lengthy (15,000 characters) and contains substantive governance disclosure information, not merely an announcement or a certification. It is not a full annual report, audit report, or management report but a specific governance disclosure document required by ASX rules. Therefore, the most appropriate classification is Governance Information (CGR).
2024-08-29 English
Application for quotation of securities - OCC 8 pages 21.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard application for quotation of securities on the ASX (Australian Securities Exchange). It details the issue of shares pursuant to an Employee Awards Plan, including the number of securities to be quoted, issue date, and other listing rule requirements. This type of document is a regulatory announcement related to capital changes, specifically the issuance and quotation of new shares. It is not a full financial report, earnings release, or management report, but rather a formal notification of a capital change event. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely an announcement of a report but a substantive filing about securities issuance.
2024-08-07 English
Notification regarding unquoted securities - OCC 8 pages 21.6KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme. It includes specifics such as the number of securities issued, dates, and references to ASX listing rules. The content is a formal notification of a securities issue rather than a financial report or earnings release. It does not contain financial statements or management discussion but focuses on capital changes related to securities issuance. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length (7274 characters) supports it being a full notification rather than a brief announcement or a report publication announcement.
2024-08-07 English
Striate Expansion Continues with Singapore Application 2 pages 235.0KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing Orthocell's submission of a regulatory application to the Health Services Authority of Singapore for approval to market and sell its product Striate+. It discusses the company's regulatory strategy, market expansion, recent approvals, revenue growth, and financial position. There are no detailed financial statements, quarterly or annual reports, or audit information included. The document is primarily an update on regulatory and commercial progress, not a financial report or detailed investor presentation. It is not a certification or voting result announcement. The length is 6881 characters, which is sufficient for a detailed announcement but does not contain substantive financial data or report content. Therefore, this document fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance updates that do not fit other categories.
2024-07-28 English
Global Market Expansion Accelerates - New Regions Pending 4 pages 595.0KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing Orthocell's accelerated global market expansion plans for its medical devices Striate+ and Remplir, including details on regulatory applications submitted or planned in various markets. It highlights record revenues for FY24 and discusses market opportunities and regulatory strategies. There are no detailed financial statements, audit information, or comprehensive management discussion of financial results. The document is primarily an update on regulatory filings and market expansion plans, not a formal financial report or earnings release. It is also not a certification, voting result, or legal proceeding. Given the nature of the content as a corporate announcement about regulatory applications and market expansion, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (9467 characters) and content confirm it is not merely a brief announcement of a report publication but a substantive regulatory update.
2024-07-23 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.